346 related articles for article (PubMed ID: 30260409)
1. Evaluation of dalbavancin alone and in combination with β-lactam antibiotics against resistant phenotypes of Staphylococcus aureus.
Xhemali X; Smith JR; Kebriaei R; Rice SA; Stamper KC; Compton M; Singh NB; Jahanbakhsh S; Rybak MJ
J Antimicrob Chemother; 2019 Jan; 74(1):82-86. PubMed ID: 30260409
[TBL] [Abstract][Full Text] [Related]
2. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
Kebriaei R; Rice SA; Stamper KC; Rybak MJ
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
[TBL] [Abstract][Full Text] [Related]
3. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Smith JR; Yim J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
[TBL] [Abstract][Full Text] [Related]
4. Combinations of (lipo)glycopeptides with β-lactams against MRSA: susceptibility insights.
Kebriaei R; Rice SA; Singh NB; Stamper KC; Nguyen L; Sheikh Z; Rybak MJ
J Antimicrob Chemother; 2020 Oct; 75(10):2894-2901. PubMed ID: 32591820
[TBL] [Abstract][Full Text] [Related]
5. Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus.
Werth BJ; Ashford NK; Penewit K; Waalkes A; Holmes EA; Ross DH; Shen T; Hines KM; Salipante SJ; Xu L
Clin Microbiol Infect; 2021 Jun; 27(6):910.e1-910.e8. PubMed ID: 32866650
[TBL] [Abstract][Full Text] [Related]
6. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013).
Huband MD; Castanheira M; Farrell DJ; Flamm RK; Jones RN; Sader HS; Mendes RE
Int J Antimicrob Agents; 2016 Jun; 47(6):495-9. PubMed ID: 27211209
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
Jones RN; Fritsche TR; Sader HS; Goldstein BP
J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
[TBL] [Abstract][Full Text] [Related]
9. β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA.
Tran N; Rybak MJ
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555635
[TBL] [Abstract][Full Text] [Related]
10. Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.
Biedenbach DJ; Ross JE; Fritsche TR; Sader HS; Jones RN
J Clin Microbiol; 2007 Mar; 45(3):998-1004. PubMed ID: 17215346
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of daptomycin combined with dalbavancin and linezolid, and dalbavancin with linezolid against MRSA strains.
Aktas G; Derbentli S
J Antimicrob Chemother; 2017 Feb; 72(2):441-443. PubMed ID: 28073963
[TBL] [Abstract][Full Text] [Related]
12. Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target.
Lepak A; Marchillo K; VanHecker J; Andes D
Antimicrob Agents Chemother; 2015 Dec; 59(12):7833-6. PubMed ID: 26392492
[TBL] [Abstract][Full Text] [Related]
13. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
[TBL] [Abstract][Full Text] [Related]
14. Bactericidal activity and resistance development profiling of dalbavancin.
Goldstein BP; Draghi DC; Sheehan DJ; Hogan P; Sahm DF
Antimicrob Agents Chemother; 2007 Apr; 51(4):1150-4. PubMed ID: 17220411
[TBL] [Abstract][Full Text] [Related]
15. Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis.
Kussmann M; Karer M; Obermueller M; Schmidt K; Barousch W; Moser D; Nehr M; Ramharter M; Poeppl W; Makristathis A; Winkler S; Thalhammer F; Burgmann H; Lagler H
Emerg Microbes Infect; 2018 Dec; 7(1):202. PubMed ID: 30514923
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers.
Sader HS; Mendes RE; Duncan LR; Pfaller MA; Flamm RK
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263077
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.
Sader HS; Mendes RE; Pfaller MA; Flamm RK
J Antimicrob Chemother; 2019 May; 74(5):1306-1310. PubMed ID: 30753485
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro.
Dilworth TJ; Sliwinski J; Ryan K; Dodd M; Mercier RC
Antimicrob Agents Chemother; 2014; 58(2):1028-33. PubMed ID: 24277036
[TBL] [Abstract][Full Text] [Related]
19. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus.
Rand KH; Houck HJ
Antimicrob Agents Chemother; 2004 Aug; 48(8):2871-5. PubMed ID: 15273094
[TBL] [Abstract][Full Text] [Related]
20. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
Dilworth TJ; Leonard SN; Vilay AM; Mercier RC
Clin Ther; 2014 Oct; 36(10):1334-44. PubMed ID: 25066667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
